ASP3652
Phase 2Small molecule
AstellasASP3652 is one of 55 small molecule programs targeting Prostatitis. It is currently in Phase 2.
2
Indications
8
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Interstitial Cystitis
#DrugCompanyPhaseTrials
1Onabotulinumtoxin a
LundbeckApproved
Elmiron
WWim Janssens
Approved
Myrbetriq
AstellasPhase 3
Cimzia
UCBPhase 3
Xolair
RochePhase 3
Intron a
SanofiPhase 3
Humira
CCelltrion
Phase 3
Sodium Hyaluronate
SanofiPhase 3
Quietus
Merck & Co.Phase 2
Ajovy
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Single Dose2 trials
Elderly1 trial
Metabolism1 trial
Interstitial Cystitis1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ASP3652. EMBL-EBI & Wellcome Sanger Institute.
- [4]